Evidence map›Paper›PMID 37916122›Full record

ArticleHeliyon2023

Plasma exosomal miR-1290 and miR-29c-3p as diagnostic biomarkers for lung cancer.

Qian Zhang, Kaifu Zheng, Yongheng Gao, Shihong Zhao, Yabo Zhao, Wangping Li, Yandong Nan, Zhengping Li, Wei Liu, Xinxin Wang and 3 more

Abstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Urinary biomarkers for lung cancer detection.The journal of liquid biopsy · 2026
    Article
  3. Article
  4. LncRNA RP11-510J16.3 exacerbates sepsis-associated encephalopathy by facilitating NLRP3-dependent pyroptosis through miR-1290 sequestering.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qian ZhangDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Kaifu ZhengDepartment of General Surgery, the 991th Hospital of Joint Logistic Support Force of People's Liberation Army, Xiangyang 441000, China.
Yongheng GaoDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Shihong ZhaoDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Yabo ZhaoDepartment of Thoracic surgery, Tangdu Hospital, Air Force Military Medical University, Xi'an, China.
Wangping LiDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Yandong NanDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Zhengping LiDepartment of General Surgery, the 991th Hospital of Joint Logistic Support Force of People's Liberation Army, Xiangyang 441000, China.
Wei LiuDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Xinxin WangDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Yanwei ChenDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Gang LiuDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.
Faguang JinDepartment of Respiratory and Critical Care Medicine, Tangdu Hospital, Air Force Military Medical University, Xi'an, 710038, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Enhancing the diagnostic efficacy of early-stage lung cancer is crucial for improving prognosis. The objective of this study was to ascertain dependable exosomal miRNAs as biomarkers for the diagnosis of lung cancer. Methods: Exosomal miRNA candidates were identified through miRNA sequencing and subsequently validated in various case-control sets using real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR). The correlation between the expression of exosomal miRNAs and the clinicopathological features of lung cancer was investigated. To assess the diagnostic efficacy of exosomal miRNAs for lung cancer, the receiver operating characteristic (ROC) curve analysis was conducted. The optimal cutoff value of exosomal miRNAs was determined in the testing cohort and subsequently confirmed in the validation cohort. Results: The results showed that the expression of exosomal miR-1290 was significantly elevated, while that of miR-29c-3p was significantly decreased in the plasma of lung cancer patients, especially in those with early-stage lung cancer, compared to individuals with benign lung conditions (P < 0.01). Exosomal miR-1290 and miR-29c-3p demonstrated superior diagnostic efficacy compared to conventional tumor biomarkers in distinguishing between lung cancer and benign lung diseases, as evidenced by their respective area under the curve (AUC) values of 0.934 and 0.868. Furthermore, exosomal miR-1290 and miR-29c-3p exhibited higher diagnostic efficiency in early-stage lung cancer than traditional tumor markers, with AUC values of 0.947 and 0.895, respectively. Notably, both exosomal miR-1290 and miR-29c-3p displayed substantial discriminatory capacity in distinguishing between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), as indicated by their respective AUC values of 0.810 and 0.842. Conclusions: The findings of this study provided evidence that exosomal miR-1290 and miR-29c-3p hold significant potential as biomarkers for the early detection of lung cancer, as well as for differentiating between NSCLC and SCLC.

Indexed as

DiagnosisExosomeLung NeoplasmsMiR-1290MiR-29c-3p

Identifiers

PMID37916122
PMCPMC10616353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.